© Reuters. FILE PHOTO: Vials and medical syringe are seen in front of J&J logo in this illustration
(Reuters) – Johnson & Johnson (NYSE:) on Tuesday forecast 2021 profit above Wall Street estimates and promised data from its widely watched coronavirus vaccine trial soon, as the healthcare conglomerate races to develop a potential single-dose vaccine for COVID-19.
The company had previously signaled that it expected to deliver data on the trial before the end of January, at a time when global hopes of defeating the virus are riding on securing adequate supplies of multiple vaccines.
Johnson & Johnson, which runs a large medical device business in addition to its pharmaceuticals unit, forecast 2021 adjusted profit of between $9.40 and $9.60 per share, compared with analysts’ estimates of $8.99 per share, according to IBES data from Refinitiv.
The company’s fourth-quarter profit fell 2.7% to $14.71 billion. The company reported that it had recorded litigation expenses of $2.9 billion in the fourth quarter.
J&J faces a litany of lawsuits over its marketing of opioids, its pelvic meshes and body powders.
The company’s fourth-quarter sales rose to $22.48 billion from $20.75 billion, helped by higher demand for cancer drugs.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.